Skip to content
by Legal Desire
7 December 2023

Latham & Watkins Advises Cerevel Therapeutics in Acquisition by AbbVie

Advising firms

Deal team

24 lawyers named
LawyerFirmSeniorityPracticeOffice
Charles Ruck Lead Latham & Watkins LLP Partner corporate New York
Daniel Rees Lead Latham & Watkins LLP Partner corporate Orange County
Brian Umanoff Latham & Watkins LLP Associate corporate Not stated
Jack McKay Latham & Watkins LLP Associate corporate Not stated
AJ Blair Latham & Watkins LLP Associate corporate Not stated
Courtney Lem Latham & Watkins LLP Associate corporate Not stated
Danny Del Giorno Latham & Watkins LLP Associate corporate Not stated
Jacob Kempf Latham & Watkins LLP Associate corporate Not stated
Greg Rodgers Latham & Watkins LLP Partner debt Los Angeles
Ryan Gold Latham & Watkins LLP Associate debt New York
Jekkie Kim Latham & Watkins LLP Partner intellectual property Bay Area
Billy Wu Latham & Watkins LLP Associate intellectual property Bay Area
Katharine Moir Latham & Watkins LLP Partner tax Bay Area
Rasha Suleiman Latham & Watkins LLP Associate tax Bay Area
Chad Jennings Latham & Watkins LLP Counsel FDA regulatory Washington, D.C.
Trevor Thompson Latham & Watkins LLP Associate FDA regulatory Washington, D.C.
Betty Pang Latham & Watkins LLP Partner healthcare Bay Area
Maj Vaseghi Latham & Watkins LLP Partner benefits Bay Area
Alisa Hand Latham & Watkins LLP Associate benefits Bay Area
Nimra Syed Latham & Watkins LLP Associate benefits Bay Area
Joshua Holian Latham & Watkins LLP Partner HSR Bay Area
Olivia Zacks Latham & Watkins LLP Associate HSR Bay Area
Heather Deixler Latham & Watkins LLP Partner data privacy Bay Area
Mitch Bennett Latham & Watkins LLP Associate data privacy Bay Area

Stated terms

Stated value
USD 8.70bn (US$8.7 billion)
What the figure measures
Total transaction value
Client
Cerevel TherapeuticsTarget
Counterparties
AbbVie Inc. (Buy-side)